Breaking News Instant updates and real-time market news.

ABT

Abbott

$55.47

-0.61 (-1.09%)

, DXCM

DexCom

$44.77

-0.01 (-0.02%)

10:25
10/24/17
10/24
10:25
10/24/17
10:25

Leerink medical devices analysts hold an analyst/industry conference call

Analysts discuss Continuous Glucose Monitoring (CGM) reimbursement coverage and assess the impact to coverage pricing to Dexcom's G5 CGM system with Abbott's Li on an Analyst/Industry conference call to be held on October 24 at 11 am.

ABT

Abbott

$55.47

-0.61 (-1.09%)

DXCM

DexCom

$44.77

-0.01 (-0.02%)

  • 24

    Oct

  • 01

    Nov

  • 06

    Nov

ABT Abbott
$55.47

-0.61 (-1.09%)

10/23/17
JEFF
10/23/17
NO CHANGE
Target $58
JEFF
Buy
Jefferies survey found all 60 currrent users sticking with Dexcom
Jefferies analyst Raj Denhoy surveyed 60 current users of Dexcom's (DXCM) G5 continuous glucose monitoring system and found that none plan to switch to Abbott's Libre. Approval for Libre with a favorable label and what seems to be an aggressive pricing strategy have turned Dexcom shares "toxic," Denhoy tells investors in a research note titled "What To Do With DXCM? Our Survey Says Stick With It". The analyst says that while competition will likely hurt Dexcom's near-term growth, the survey of current continuous glucose monitoring users and conversations with doctors suggest the company's outlook "might not be so dire." He cut his price target for the shares to $58 from $91 and keeps a Buy rating on the name.
10/19/17
RBCM
10/19/17
NO CHANGE
Target $60
RBCM
Outperform
Abbott price target raised to $60 from $55 at RBC Capital
RBC Capital analyst Glenn Navarro raised his price target on Abbott after Q3 results, citing steady improvement in Medical Devices, return to double-digit growth in Established Pharmaceuticals and prospects for faster U.S. growth in Diagnostics. Navarro says revenue growth will likely accelerate in FY18, maintaining an Outperform rating on Abbott.
10/19/17
COWN
10/19/17
NO CHANGE
Target $68
COWN
Outperform
Abbott price target raised to $68 from $55 at Cowen
Cowen analyst Joshua Jennings raised his price target on Abbott to $68 from $55 following better than expected Q3 results. The analyst also noted the company raised its guidance and he expects operational sales growth to tick higher in Q4. Jennings reiterated his Outperform rating on Abbott shares.
10/19/17
JEFF
10/19/17
NO CHANGE
Target $65
JEFF
Buy
Abbott price target raised to $65 from $58 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Abbott Laboratories to $65 saying the Q3 results provide more evidence that the sales and earnings growth story is working. Better sales growth justifies a higher multiple, Denhoy tells investors in a post-earnings research note. He keeps a Buy rating on the shares.
DXCM DexCom
$44.77

-0.01 (-0.02%)

10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
J&J exit from insulin pumps a 'clear win' for Medtronic, says Piper Jaffray
After Animas, one of Johnson & Johnson's (JNJ) companies, announced that it intends to discontinue the manufacturing and sale of insulin pumps and selected Medtronic (MDT) as its transition partner, Piper Jaffray analyst Matt O'Brien called the news a "clear win" for Medtronic. For DexCom (DXCM), which has partnered with Animas, this decision is likely a modest negative, while Insulet (PODD) and Tandem (TNDM) may be able to capture some share from Animas pump patients who look for other therapeutic options, added O'Brien.
10/04/17
WEDB
10/04/17
NO CHANGE
Target $76
WEDB
Outperform
Dexcom still well positioned to generate 'healthy growth rates,' says Wedbush
Wedbush analyst Tao Levy continues to believe Dexcom (DXCM) offers the best-in-class technology and from a practical standpoint views Abbott's (ABT) Libre's accuracy and 12hr warm-up period as dynamics which may limit uptake among the Type 1 diabetes community. As a result, the analyst believes Dexcom remains well positioned to generate healthy growth rates, despite Abbott's Libre upcoming U.S. launch, given the combination of a large, under-penetrated market opportunity, and diverse technology preferences among people with diabetes. He reiterates an Outperform rating and $76 price target on Dexcom's shares.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$229.73

-1.28 (-0.55%)

09:50
07/17/18
07/17
09:50
07/17/18
09:50
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs »

Goldman Sachs sees 2H…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HFC

HollyFrontier

$68.75

-0.165 (-0.24%)

09:50
07/17/18
07/17
09:50
07/17/18
09:50
Options
Repeat of bullish vertical spreads in HollyFrontier »

Repeat of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

TXT

Textron

$66.80

0.13 (0.19%)

09:49
07/17/18
07/17
09:49
07/17/18
09:49
Technical Analysis
Technical Earnings Preview: Textron near highs before news »

The stock is in a strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GS

Goldman Sachs

$230.50

-0.51 (-0.22%)

09:48
07/17/18
07/17
09:48
07/17/18
09:48
Hot Stocks
Goldman Sachs CFO says investment banking backlog reached record in Q2 »

Goldman Sachs CFO Marty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:48
07/17/18
07/17
09:48
07/17/18
09:48
Conference/Events
Cowen Internet & new media analyst to hold an analyst/industry conference call »

Internet & New Media…

09:47
07/17/18
07/17
09:47
07/17/18
09:47
General news
Netflix slide leading Nasdaq to struggle at open »

Stock futures fell during…

SERV

ServiceMaster

$61.85

(0.00%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
ServiceMaster falls -5.7% »

ServiceMaster is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

HZN

Horizon Global

$6.89

(0.00%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
Horizon Global falls -6.6% »

Horizon Global is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMC

Omnicom

$72.81

-5.31 (-6.80%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
Omnicom falls -6.9% »

Omnicom is down -6.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 09

    Aug

IGT

International Game

$25.17

0.78 (3.20%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
International Game rises 3.5% »

International Game is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

GOL

Gol Linhas

$6.66

0.27 (4.23%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
Gol Linhas rises 3.8% »

Gol Linhas is up 3.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPI

Farmland Partners

$6.54

0.445 (7.30%)

09:47
07/17/18
07/17
09:47
07/17/18
09:47
Hot Stocks
Farmland Partners rises 7.0% »

Farmland Partners is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATM

Cardtronics

$26.60

(0.00%)

09:46
07/17/18
07/17
09:46
07/17/18
09:46
Recommendations
Cardtronics analyst commentary  »

Cardtronics immediate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

09:45
07/17/18
07/17
09:45
07/17/18
09:45
General news
Housing Market Index to be reported at 10:00 »

July Housing Market Index…

09:45
07/17/18
07/17
09:45
07/17/18
09:45
General news
Breaking General news story  »

Federal Reserve Chairman…

CMCSA

Comcast

$34.98

(0.00%)

, CMCSK

Comcast

$0.00

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Periodicals
NBCU relaunches Craftsy as subscription-video service Bluprint, Variety reports »

NBCUniversal Cable…

CMCSA

Comcast

$34.98

(0.00%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$124.70

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Hot Stocks
Johnson & Johnson says 'disappointed' in Spine & Knee medical sales results »

Says Spine still an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 08

    Aug

BA

Boeing

$356.01

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Hot Stocks
Boeing, Xiamen Airlines announce optimized maintenance program deal »

Boeing and Xiamen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SNA

Snap-On

$163.93

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Recommendations
Snap-On analyst commentary  »

Snap-On checks point to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 16

    Aug

VEON

Veon

$3.05

(0.00%)

, HFC

HollyFrontier

$68.91

(0.00%)

09:40
07/17/18
07/17
09:40
07/17/18
09:40
Options
Unusually active option classes on open July 17th »

Unusual total active…

VEON

Veon

$3.05

(0.00%)

HFC

HollyFrontier

$68.91

(0.00%)

DUST

Direxion Daily Gold Miners Bear 3X ETF

$25.49

(0.00%)

UNH

UnitedHealth

$257.03

(0.00%)

JNJ

Johnson & Johnson

$124.70

(0.00%)

CZR

Caesars

$11.63

(0.00%)

GS

Goldman Sachs

$231.01

(0.00%)

MCD

McDonald's

$158.76

(0.00%)

ATVI

Activision Blizzard

$80.23

(0.00%)

GDX

Market Vector Gold Miners

$21.88

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

09:38
07/17/18
07/17
09:38
07/17/18
09:38
Recommendations
Netflix analyst commentary  »

Netflix Q2 weakness is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$194.01

-2 (-1.02%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Initiation
Wex initiated  »

Wex initiated with a Peer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$231.01

4.71 (2.08%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Periodicals
Lloyd Blankfein writes farewell memo to Goldman Sachs team, NY Times reports »

Goldman Sachs CEO LLoyd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$58.79

1.04 (1.80%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Recommendations
Nevro analyst commentary  »

Nevro price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

FLT

FleetCor

$216.11

-4.06 (-1.84%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FleetCor initiated  »

FleetCor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.